Cumberland Pharma | 10-Q: FY2025 Q3 Revenue: USD 8.292 M

Revenue: As of FY2025 Q3, the actual value is USD 8.292 M.

EPS: As of FY2025 Q3, the actual value is USD -0.13.

EBIT: As of FY2025 Q3, the actual value is USD -1.987 M.

Net Revenues: For the three months ended September 30, 2025, net revenues were $8.3 million, compared to $9.1 million for the same period in 2024. For the nine months ended September 30, 2025, net revenues were $30.8 million, compared to $27.4 million in 2024, an increase of $3.4 million.

Operating Loss: The operating loss for the three months ended September 30, 2025, was -$1.97 million, compared to -$1.69 million for the same period in 2024. For the nine months ended September 30, 2025, the operating loss was -$1.42 million, compared to -$4.59 million in 2024.
Net Loss: The net loss for the three months ended September 30, 2025, was -$1.95 million, compared to -$1.54 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was -$1.44 million, compared to -$4.54 million in 2024.

Operating Cash Flow: Net cash provided by operating activities for the nine months ended September 30, 2025, was $4.93 million, compared to net cash used in operating activities of -$2.52 million for the same period in 2024.
Free Cash Flow: Not explicitly stated, but the net decrease in cash and cash equivalents for the nine months ended September 30, 2025, was -$2.77 million.

Vibativ Contribution: For the three months ended September 30, 2025, Vibativ contributed $1.47 million, compared to $0.49 million for the same period in 2024. For the nine months ended September 30, 2025, Vibativ contributed $6.45 million, compared to $2.65 million in 2024.
Sancuso Contribution: For the three months ended September 30, 2025, Sancuso contributed $2.11 million, compared to $1.40 million for the same period in 2024. For the nine months ended September 30, 2025, Sancuso contributed $5.24 million, compared to $3.33 million in 2024.

Core Business Focus: Cumberland Pharmaceuticals Inc. aims to maximize the potential of existing brands while building a portfolio of differentiated products. The company is focused on expanding its brands into new patient populations through clinical trials and new product presentations. Additionally, Cumberland is developing a pipeline of new product candidates to address unmet medical needs and is pursuing opportunities to acquire additional marketed brands and late-stage development product candidates.
Non-Core Business: The company is building international partnerships to bring its medicines to patients in other countries and is leveraging its infrastructure through co-promotion partnerships to drive prescription volume and product sales. Cumberland is also managing its operations with financial discipline to deliver positive cash flow from operations.